We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 91% above its sector, the market expects faster growth.
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6667.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
